As a result, patients with LC with a significant imbalance in the ADAMTS13 enzyme–VWF substrate had a higher risk of mortality than those without this imbalance [2,13,14], i.e., ADAMTS13:AC and VWF:Ag have become useful prognostic biomarkers for patients with LC [2,13,14]. The gene discussed is ADAMTS13; the disease is laryngotracheoesophageal cleft.